Alterative effects of an oral alginate extract on experimental rabbit osteoarthritis
© Lu et al. 2015
Received: 8 June 2015
Accepted: 21 July 2015
Published: 4 August 2015
Osteoarthritis (OA) is a common joint disease that causes disabilities in elderly. However, few agents with high efficacy and low side effects have been developed to treat OA. In this study, we evaluated the effects of the alginate extract named CTX in OA cell and rabbit models.
CTX was formulated by hydrolyzing sodium alginate polymers with alginate lyase and then mixing with pectin. HPLC was used to analyze the CTX content. Human chondrosarcoma SW1353 cells treated with interleukin-1β were used as OA model cells to investigate the effects of CTX on chondrocyte inflammation and anabolism. CTX at concentrations up to 1000 μg/ml exerted low cytotoxicity. It inhibited the gene expression of proinflammatory matrix metalloproteinases (MMPs) including MMP1, MMP3 and MMP13 in a dose-dependent manner and increased the mRNA level of aggrecan, the major proteoglycan in articular cartilage, at 1000 μg/ml. Thirteen-week-old New Zealand White rabbits underwent a surgical anterior cruciate ligament transection and were orally treated with normal saline, glucosamine or CTX for up to 7 weeks. Examinations of the rabbit femur and tibia samples demonstrated that the rabbits taking oral CTX at a dosage of 30 mg/kg/day suffered lesser degrees of articular stiffness and histological cartilage damage than the control rabbits.
The gene expression profiles in the cell and the examinations done on the rabbit cartilage suggest that the alginate extract CTX is a pharmaco-therapeutic agent applicable for OA therapy.
Osteoarthritis (OA) is a gradually progressing disorder affecting mammalian joints in which the articular cartilage and the surrounding extracellular matrix (ECM) are destroyed [1, 2]. An imbalance between the repair and degradation of the cartilage may disrupt the collagen matrix, resulting in OA. The pathologic changes include proteoglycan degradation, type II collagen degradation, and eventually local or complete loss of the cartilage matrix . Cytokines and their downstream targets are major players in the pathogenesis of OA [4, 5]. Pro-inflammatory cytokines such as interleukin (IL)-1β are produced by activated synoviocytes and articular chondrocytes and promotes the expression of several matrix metalloproteinases (MMPs), including MMP-1, MMP-3, and MMP-13 [6–8]. Many studies demonstrated that chondrosarcoma SW1353 cells challenged with IL-1β show similarities to primary human osteoarthritic chondrocytes [8–11]. IL-1β induces nuclear factor κ-B (NFκB) as a common transcriptional regulator resulting in a strong induction of those MMPs and the other cytokine IL-6 in both SW1353 cells and primary human chondrocytes. IL-1β-treated SW1353 cells can be of value to serve as a model for OA.
The development of OA therapeutics focuses primarily on disease-modifying OA drugs (DMOADs) and connective tissue structure-modifying agents (CTSMAs) [12–15]. Our team as well as others showed OA-relieving effects of injectable hyaluronan, a polysaccharide and major component of the cartilage, and suggested it as a long-lasting therapeutic agent for OA [10, 16, 17]. A noninvasive dietary supplement of glucosamine has been used to treat OA and is available clinically in some areas; however, it may increase the risk of developing diabetes with high dosages in long-term therapy . Another polysaccharide, alginate, is a potential OA therapeutic agent which has also been studied in the form of injectable hydrogels in cartilage regeneration [19, 20]. It would be worth investigating the effects of orally administered alginate.
Alginate is a family of natural polysaccharides distributed in the cell walls of algae. It has a great potential for use in biomedical applications, especially in tissue engineering because of its non-toxic nature, gentle sol/gel transition procedure and low cost [21–24]. Moreover, alginate oligosaccharides produced by enzymatic degradation of alginate polymers are also known to have several biological activities including suppression of fibroblast proliferation and collagen synthesis in human skin, stimulation of endothelial cell growth and migration, stimulation of human keratinocyte growth, and suppression of Th2 development and IgE secretion [22, 25, 26]. Results suggest that alginate is useful for the treatment of disorders related to abnormal collagen metabolism such as OA.
Recent studies suggest that OA progression is associated with biomarkers of synthesis, degradation and inflammation of collagen ; however, these markers are usually nonspecific to OA. The severity of OA is clinically estimated by radiation or magnetic resonance imaging. To show pathological evidence on experimental animals, macroscopic and histologic examinations are mostly used.
In this study, we hypothesize that the alginate extract named CTX administered orally exerts alterative effects in OA model cells and animals.
Preparation of the alginate extract CTX
An alginate oligosaccharide (oligomer) solution was obtained by hydrolyzing sodium alginate polymers (~220 kDa) (Junsei Chemical Co., Japan) with alginate lyase (Sigma Adrich, U.S.A.) in distilled water at 40 °C for 24 h. CTX was formulated by mixing the alginate oligomers with pectin (Duksan Science, Korea) in a solution at 9:1 ratio and dried in a spray dryer. Alginate polymers and oligomers were determined by an HPLC (Shimadzu 10AVP series) with Supelcogel-H column (Sigma Aldrich, USA), and the procedure was modified from a protocol described elsewhere . Briefly, the column temperature was 75 °C and the flow rate was 0.6 ml/min. Phosphoric acid at 0.1 % as mobile phase along with a UV detector wavelength at 210 nm were used for alginate polymer analysis; deionized water as mobile phase along with a refractive index detector were used for alginate oligomer analysis. To determine the molecular weight, the formulated CTX was analyzed by gel permeation chromatography with 0.1 M NaNO3 as mobile phase in Shodex Asahipak GS-320/220 columns at 35 °C.
The human chondrosarcoma SW1353 cell line was obtained from the ATCC (American Type Culture Collection) . SW1353 cells were cultured in L-15 medium supplemented with 10 % fetal bovine serum (FBS) and 1 % L-glutamine in a humidified incubator with 5 % CO2 at 37 °C. Cells at 105/ml were pretreated with 0, 10, 100 or 1000 μg/ml CTX for 30 min and stimulated with 5 ng/mL recombinant human IL-1β (R&D Systems Inc.) for up to 24 h. The cells were then collected and analyzed as indicated.
Cell viability assay
SW1353 cells were cultured in 24-well flat-bottomed tissue culture plates and treated with 0, 10, 100 or 1000 μg/ml CTX (sterilized with 0.22 μm filter) for 24 h. After incubation, the medium was replaced with 100 μl of a mixture of a ratio of 1:9 composing MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) and medium. Cells were then incubated for 2 h and analyzed at an absorbance of 550 nm. The rate of tetrazolium reduction is proportional to the cell number.
Reverse transcription-polymerase chain reaction (RT–PCR)
Primer sequences for RT-PCR
5’-CCT TCT ACC CGG AAG TTG AG-3’
5’-TCC GTG TAG CAC ATT CTG TC-3’
5’-GAA AGT CTG GGA AGA GGT GAC-3’
5’-AAC CGA GTC AGG TCT GTG AG-3’
5’-GAA TTA AGG AGC ATG GCG AC-3’
5’-TAA GGA GTG GCC GAA CTC AT-3’
5’-TGA GGA GGG CTG GAA CAA GTA CC-3’
5’-GGA GGT GGT AAT TGC AGG GAA CA-3’
5’-ACA CTG TGC CCA TCT ACG AG-3’
5’-TAC AGG TCT TTG CGG ATG TC-3’
Thirteen-week-old New Zealand White male rabbits with mature skeletons were used as the experimental OA animals. The animals were kept in steel cages (35 × 53 × 35 cm) (W × D × H) individually at 22 ± 3 °C and 55 ± 20 % humidity. Animals were fed RC4 pellet-type laboratory-animal food. There was no extra calcium supplied, and tap water was given freely. All animal procedures were approved by the Institutional Animal Care and Use Committee at Taipei Medical University.
Experimental OA model
Rabbits were divided into five groups of ten each. Four groups were experimental OA-induced animals prepared according to the protocol of an anterior cruciate ligment transection (ACLT) . The rabbits were anesthetized using a combination of Zoletil (Tiletamine + Zolezepam) (Zoletil-Virbac, Carros, France) and Rompun (Bayer, Leverkusen, Germany). Their right knee joints were incised aseptically two cm down the lateral aspect of the patella to expose and cut the anterior cruciate ligment. The subdermal muscular layer and skin was sewn by knotting absorbable and nylon sutures. Antibiotics were applied subcutaneously near the thigh.
The group that did not undergo the ACLT procedure (normal) and one group with ACLT were fed normal saline to serve as controls. The other three groups were fed either glucosamine (10 mg/kg/day) or CTX (10 or 30 mg/kg/day). All agents were administered orally from the first day of the ACLT procedure to 7 weeks.
The experimental OA rabbits were orally treated with normal saline (10 mg/kg/day), glucosamine (10 mg/kg/day) or CTX (10 or 30 mg/kg/day). Both hind paws of the rabbits were weighed the day before the surgery and weekly up to seven weeks after the surgery. The percent (%) weight distribution of the experimental right hind paw was calculated as described [17, 30].
After the rabbits were euthanized, knee joint specimens were collected by osteotomy 3 cm above and below the joints and fixed in 10 % buffered formalin (pH 7.4) for 24 h. Fixed specimens were cleared of soft tissues and ligaments allowing the gross examination of the articular surfaces of the femoral condyles and tibial plateaus.
Macroscopic scoring parameters
Articular cartilage abnormality
2 small or l large
3 small or 2 large
Loss of superficial layer
Histological (microscopic) examination
Histopathological scoring parameters
Normal matrix and chondrocytes
Uneven cartilage surface with loss of metachromasia around the enlarged cartilage of superficial zone. No fibrillation chondrocyte clusters
Some surface erosion, fibrillation and small chondrocyte clusters in superficial zone decreased metachromasia extending to the deep zone
Deeper surface erosion with fibrillation extending into the deep zone, large number of chondrocyte clusters containing several cells, major degenerative changes and loss of metachromasia in the cartilage matrix
At least three independent sets of experiment were performed. Results were analyzed using SigmaPlot 12.5 software. Statistical analysis was done with Student’s t test and one way ANOVA. Differences were considered significant if p < 0.05 (*) or 0.01 (**).
CTX inverted OA pathogenesis in vitro
When the OA model cells were treated with CTX for 6 h, their mRNA expressions of MMP-1, MMP-3, MMP-13 and aggrecan were analyzed using RT-PCR. As expected, IL-1β induced mRNA levels of the MMPs in the cells (Fig. 1b). CTX reduced their expressions in a dose-dependent manner with a significant difference at 100 μg/ml for MMP3 and MMP13 and 1000 μg/ml for all the MMPs, suggesting an anti-inflammatory effect of the agent. Furthermore aggrecan, the major proteoglycan found in the articular cartilage , was dramatically increased by CTX at 1000 μg/ml, indicating a counteracting effect of CTX on OA pathogenesis.
Animals recovered from OA with oral CTX
OA tissue repaired with CTX treatment
In our study, alginate extracted CTX was suggested as a potential agent to promote matrix anabolism and stimulated cartilage regeneration. In the OA model cells, we found an effective treatment of CTX at 1000 μg/ml in reducing MMPs and promoting aggrecan expression although the effects were not obvious at low CTX (Fig. 1b). Aggrecan is important for cartilage elasticity, toughness and shock-absorbing capacity. Its degradation is a significant event in the early-stage OA . Indeed, CTX improved cartilage structure restoration although it did not serve as an analgesic in the OA model rabbits (Figs. 3 and 4). Based on our data, we suggest that the CTX provide therapeutic effects for OA.
Although the etiology of OA is still intensively debated, its pathological features are well established. OA is composed by a group of overlapping distinct diseases, which may have different etiologies with similar biologic, morphologic, and clinical outcomes. The disease not only affects the articular cartilage, but also involves the entire joint, including the subchondral bone, ligaments, capsule, synovial membrane, and periarticular muscles . Ultimately, the articular cartilage degenerates with fibrillation, fissures, ulceration, and loss of the joint surface. Studies showed hydrogel-based alginate possesses high viscosity and viscoelasticity which may provide good chondro-protective effects . The mechanism how orally administered alginate exerts its function in articular cartilage is not known; however, our results suggest that CTX can prevent joint abrasion in early stages of OA. The digested alginate could be transformed into other glycans of the cartilage.
The group treated with 10 mg/kg/day CTX displayed an increase in fissures and osteophytes/chondrocytes (Fig. 3). This may suggest an on-going process of a feedback phenomenon, in which a greater amount of chondrocytes are recruited for the production of proteoglycan. CTX can increase aggrecan and decrease the MMPs production in chondrocytes (Fig. 1b). As erosion and loss of cartilage occurred, the remaining chondrocytes secreted more glycoprotein for bone regeneration, resulting in the production of osteophytes . Thus, CTX represents an ideal DMOAD and CTSMA; however, its long-term therapeutic effects on chronic OA may need further investigation.
The alginate extract CTX was found to invert OA pathogenesis in vitro by increasing aggrecan and decreasing MMPs production in the cells. It also exerted a beneficial ability in vivo by promoting regeneration of cartilaginous tissue. Therefore, CTX may be used in OA therapy.
This work was financially supported by Taipei Medical University Hospital (103TMU-TMUH-08) and Ministry of Science and Technology in Taiwan (MOST 103-2320-B-038-042).
- Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, et al. The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthritis Cartilage. 2007;15(7):819–23.PubMed CentralPubMedView ArticleGoogle Scholar
- Yelin E. Arthritis. The cumulative impact of a common chronic condition. Arthritis Rheum. 1992;35(5):489–97.PubMedGoogle Scholar
- Homandberg GA. Cartilage damage by matrix degradation products: fibronectin fragments. Clin Orthop Relat Res. 2001;(391 Suppl):S100-107.Google Scholar
- Daheshia M, Yao JQ. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol. 2008;35(12):2306–12.PubMedView ArticleGoogle Scholar
- Kardel R, Ulfgren AK, Reinholt FP, Holmlund A. Inflammatory cell and cytokine patterns in patients with painful clicking and osteoarthritis in the temporomandibular joint. Int J Oral Maxillofac Surg. 2003;32(4):390–6.PubMedView ArticleGoogle Scholar
- Fan Z, Yang H, Bau B, Soder S, Aigner T. Role of mitogen-activated protein kinases and NFkappaB on IL-1beta-induced effects on collagen type II, MMP-1 and 13 mRNA expression in normal articular human chondrocytes. Rheumatol Int. 2006;26(10):900–3.PubMedView ArticleGoogle Scholar
- Hiramitsu T, Yasuda T, Ito H, Shimizu M, Julovi SM, Kakinuma T, et al. Intercellular adhesion molecule-1 mediates the inhibitory effects of hyaluronan on interleukin-1beta-induced matrix metalloproteinase production in rheumatoid synovial fibroblasts via down-regulation of NF-kappaB and p38. Rheumatology (Oxford). 2006;45(7):824–32.View ArticleGoogle Scholar
- Chao PZ, Hsieh MS, Cheng CW, Lin YF, Chen CH. Regulation of MMP-3 expression and secretion by the chemokine eotaxin-1 in human chondrocytes. J Biomed Sci. 2011;18(1):86.PubMed CentralPubMedView ArticleGoogle Scholar
- Wang KC, Lin YF, Qin CH, Chen TL, Chen CH. Bisphenol-A interferes with estradiol-mediated protection in osteoarthritic chondrocytes. Toxicol Lett. 2010;198(2):127–33.PubMedView ArticleGoogle Scholar
- Chang CC, Hsieh MS, Liao ST, Chen YH, Cheng CW, Huang PT, et al. Hyaluronan regulates PPARgamma and inflammatory responses in IL-1beta-stimulated human chondrosarcoma cells, a model for osteoarthritis. Carbohydr Polym. 2012;90(2):1168–75.PubMedView ArticleGoogle Scholar
- Gebauer M, Saas J, Sohler F, Haag J, Soder S, Pieper M, et al. Comparison of the chondrosarcoma cell line SW1353 with primary human adult articular chondrocytes with regard to their gene expression profile and reactivity to IL-1beta. Osteoarthritis Cartilage. 2005;13(8):697–708.PubMedView ArticleGoogle Scholar
- Hogenmiller MS, Lozada CJ. An update on osteoarthritis therapeutics. Curr Opin Rheumatol. 2006;18(3):256–60.PubMedView ArticleGoogle Scholar
- Verbruggen G. Chondroprotective drugs in degenerative joint diseases. Rheumatology (Oxford). 2006;45(2):129–38.View ArticleGoogle Scholar
- Pelletier JP, Martel-Pelletier J, Raynauld JP. Most recent developments in strategies to reduce the progression of structural changes in osteoarthritis: today and tomorrow. Arthritis Res Ther. 2006;8(2):206.PubMed CentralPubMedView ArticleGoogle Scholar
- Pelletier JP. Rationale for the use of structure-modifying drugs and agents in the treatment of osteoarthritis. Osteoarthritis Cartilage. 2004;12 Suppl A:S63-68.Google Scholar
- Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev. 2006;2, CD005321.PubMedGoogle Scholar
- Lu HT, Sheu MT, Lin YF, Lan J, Chin YP, Hsieh MS, et al. Injectable hyaluronic-acid-doxycycline hydrogel therapy in experimental rabbit osteoarthritis. BMC Vet Res. 2013;9:68.PubMed CentralPubMedView ArticleGoogle Scholar
- Lafontaine-Lacasse M, Dore G, Picard F. Hexosamines stimulate apoptosis by altering SIRT1 action and levels in rodent pancreatic beta-cells. J Endocrinol. 2011;208(1):41–9.PubMedView ArticleGoogle Scholar
- Balakrishnan B, Joshi N, Jayakrishnan A, Banerjee R. Self-crosslinked oxidized alginate/gelatin hydrogel as injectable, adhesive biomimetic scaffolds for cartilage regeneration. Acta Biomater. 2014;10(8):3650–63.PubMedView ArticleGoogle Scholar
- Oprenyeszk F, Chausson M, Maquet V, Dubuc JE, Henrotin Y. Protective effect of a new biomaterial against the development of experimental osteoarthritis lesions in rabbit: a pilot study evaluating the intra-articular injection of alginate-chitosan beads dispersed in an hydrogel. Osteoarthritis Cartilage. 2013;21(8):1099–107.PubMedView ArticleGoogle Scholar
- Bidarra SJ, Barrias CC, Granja PL. Injectable alginate hydrogels for cell delivery in tissue engineering. Acta Biomater. 2014;10(4):1646–62.PubMedView ArticleGoogle Scholar
- Tajima S, Inoue H, Kawada A, Ishibashi A, Takahara H, Hiura N. Alginate oligosaccharides modulate cell morphology, cell proliferation and collagen expression in human skin fibroblasts in vitro. Arch Dermatol Res. 1999;291(7–8):432–6.PubMedView ArticleGoogle Scholar
- Loty S, Sautier JM, Loty C, Boulekbache H, Kokubo T, Forest N. Cartilage formation by fetal rat chondrocytes cultured in alginate beads: a proposed model for investigating tissue-biomaterial interactions. J Biomed Mater Res. 1998;42(2):213–22.PubMedView ArticleGoogle Scholar
- Ghahramanpoor MK, Hassani Najafabadi SA, Abdouss M, Bagheri F, Baghaban EM. A hydrophobically-modified alginate gel system: utility in the repair of articular cartilage defects. J Mater Sci Mater Med. 2011;22(10):2365–75.PubMedView ArticleGoogle Scholar
- Kawada A, Hiura N, Tajima S, Takahara H. Alginate oligosaccharides stimulate VEGF-mediated growth and migration of human endothelial cells. Arch Dermatol Res. 1999;291(10):542–7.PubMedView ArticleGoogle Scholar
- Yoshida T, Hirano A, Wada H, Takahashi K, Hattori M. Alginic acid oligosaccharide suppresses Th2 development and IgE production by inducing IL-12 production. Int Arch Allergy Immunol. 2004;133(3):239–47.PubMedView ArticleGoogle Scholar
- Attur M, Krasnokutsky-Samuels S, Samuels J, Abramson SB. Prognostic biomarkers in osteoarthritis. Curr Opin Rheumatol. 2013;25(1):136–44.PubMed CentralPubMedView ArticleGoogle Scholar
- Spigno G, Pizzorno T, De Faveri DM. Cellulose and hemicelluloses recovery from grape stalks. Bioresour Technol. 2008;99(10):4329–37.PubMedView ArticleGoogle Scholar
- Kikuchi T, Yamada H, Shimmei M. Effect of high molecular weight hyaluronan on cartilage degeneration in a rabbit model of osteoarthritis. Osteoarthritis Cartilage. 1996;4(2):99–110.PubMedView ArticleGoogle Scholar
- Mihara M, Higo S, Uchiyama Y, Tanabe K, Saito K. Different effects of high molecular weight sodium hyaluronate and NSAID on the progression of the cartilage degeneration in rabbit OA model. Osteoarthritis Cartilage. 2007;15(5):543–9.PubMedView ArticleGoogle Scholar
- Colombo C, Butler M, O’Byrne E, Hickman L, Swartzendruber D, Selwyn M, et al. A new model of osteoarthritis in rabbits. I. Development of knee joint pathology following lateral meniscectomy and section of the fibular collateral and sesamoid ligaments. Arthritis Rheum. 1983;26(7):875–86.PubMedView ArticleGoogle Scholar
- Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Res. 2002;12(1):19–32.PubMedView ArticleGoogle Scholar
- Huang K, Wu LD. Aggrecanase and aggrecan degradation in osteoarthritis: a review. J Int Med Res. 2008;36(6):1149–60.PubMedView ArticleGoogle Scholar
- Madry H, Luyten FP, Facchini A. Biological aspects of early osteoarthritis. Knee Surg Sports Traumatol Arthrosc. 2012;20(3):407–22.PubMedView ArticleGoogle Scholar
- Wan LQ, Jiang J, Miller DE, Guo XE, Mow VC, Lu HH. Matrix deposition modulates the viscoelastic shear properties of hydrogel-based cartilage grafts. Tissue Eng Part A. 2011;17(7–8):1111–22.PubMed CentralPubMedView ArticleGoogle Scholar
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.